Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

Sep 12, 09:30 AM

Headliner
Share
Subscribe
This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.
Share
Subscribe
Next
Pharma Pulse: FDA Accelerates Non-Opioid Pain Drug Development, FTC Targets Non-Competes in Healthcare, and DHL Expands Last-Mile Logistics
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce